158
Participants
Start Date
May 17, 2021
Primary Completion Date
August 7, 2027
Study Completion Date
August 7, 2027
Tofersen
Administered as specified in the treatment arm
Placebo
Administered as specified in the treatment arm
Macquarie University, Sydney
UZ Leuven, Leuven
Hanyang University Seoul Hospital, Seoul
Columbia University Medical Center, New York
Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino
Johns Hopkins Hospital, Baltimore
Medizinische Hochschule Hannover, Hanover
University of Miami School of Medicine, Miami
Holy Cross Hospital Phil Smith Neuroscience Institute, Fort Lauderdale
Hospital Universitari i Politecnic La Fe, Valencia
Northwestern Medicine, Chicago
Washington University School of Medicine, St Louis
Groupe Hospitalier Pitie-Salpetriere, Paris
Austin Neuromuscular Center, Austin
HonorHealth Neurology, Scottsdale
Universitaetsklinikum Ulm, Ulm
University Hospital of Umea, Umeå
California Pacific Medical Center Research Institute, San Francisco
University of California San Diego Medical Center, La Jolla
The Emory Clinic, Atlanta
Massachusetts General Hospital, Charlestown
Hospital Sao Paulo, São Paulo
University of Calgary, Calgary
Sunnybrook Health Sciences Centre, Toronto
Genge Partners Inc., Montreal
Kagoshima University Hospital, Kagoshima
University of Tokyo Hospital, Bunkyō City
NeuroProtect Sp. z o.o., Warsaw
University of Sheffield, Sheffield
Lead Sponsor
Biogen
INDUSTRY